Published in Thorax on November 01, 2004
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev (2012) 4.39
Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A (2007) 4.06
The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol (2008) 3.85
The versatility and adaptation of bacteria from the genus Stenotrophomonas. Nat Rev Microbiol (2009) 3.00
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 2.60
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol (2006) 1.45
Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis (2006) 1.39
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of nonfermenting gram-negative bacilli isolated from cultures from cystic fibrosis patients. J Clin Microbiol (2012) 1.25
Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care (2006) 1.02
Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol (2010) 0.99
Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis. J Clin Microbiol (2006) 0.93
Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers. Int Arch Med (2008) 0.93
Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros (2012) 0.92
Children and young adults with CF in the USA have better lung function compared with the UK. Thorax (2014) 0.86
Identification and management of unusual pathogens in cystic fibrosis. J R Soc Med (2008) 0.82
Update on host-pathogen interactions in cystic fibrosis lung disease. Mol Cell Pediatr (2016) 0.81
Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus. PLoS One (2016) 0.80
Recurrent hemoptysis with Penicillium marneffei and Stenotrophomonas maltophilia in Job's syndrome. Can Respir J (2009) 0.79
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. J Cyst Fibros (2011) 0.77
Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients. PeerJ (2015) 0.77
Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros (2015) 0.76
Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings. Microbiol Insights (2013) 0.76
Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa. PLoS One (2017) 0.75
Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis. Thorax (2004) 0.75
Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection. PLoS One (2017) 0.75
The changing epidemiology of cystic fibrosis. J Pediatr (1993) 5.50
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev (1998) 5.33
The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr (1998) 5.08
Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis (1998) 4.82
Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr (1985) 4.26
Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect (2002) 2.01
Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol (1999) 1.64
Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.46
Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol (2001) 1.43
Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child (1992) 1.31
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol (1998) 1.26
Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. Infection (1995) 1.19
Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis (1996) 1.19
Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol (2000) 1.00
Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest (2002) 0.99
Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis. Infection (1987) 0.83
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med (1994) 7.98
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis (2000) 4.93
Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis (1998) 4.82
Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol (1997) 2.65
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol (2001) 2.24
Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr (1994) 2.10
Medical ethics: an annotated bibliography. Ann Intern Med (1994) 2.03
The family conference as a focus to improve communication about end-of-life care in the intensive care unit: opportunities for improvement. Crit Care Med (2001) 2.03
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol (1989) 1.82
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis (1999) 1.79
Aggressive medical care at the end of life. Does capitated reimbursement encourage the right care for the wrong reason? JAMA (1997) 1.74
Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest (1996) 1.70
Implications of extubation delay in brain-injured patients meeting standard weaning criteria. Am J Respir Crit Care Med (2000) 1.70
Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis (1993) 1.63
Disposition of drugs in cystic fibrosis. III. Acetaminophen. Clin Pharmacol Ther (1991) 1.59
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther (2001) 1.58
Heterogeneity and disparities in the use of exception scores in pediatric liver allocation. Am J Transplant (2015) 1.54
Variations in intensive care unit utilization for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia: importance of hospital characteristics and geographic location. Crit Care Med (1998) 1.52
Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax (2001) 1.37
Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med (1997) 1.28
The effect of acute respiratory distress syndrome on long-term survival. Am J Respir Crit Care Med (1999) 1.25
Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis. Am J Respir Crit Care Med (1997) 1.15
Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros (2009) 1.13
Changes in marketplace demand for physicians: a study of medical journal recruitment advertisements. JAMA (1996) 1.11
The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. Adv Drug Deliv Rev (2002) 1.09
Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest (1996) 1.07
The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis (2001) 1.06
Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis (1986) 1.06
Effect of heat delivery and extraction on airway conductance in normal and in asthmatic subjects. Am Rev Respir Dis (1985) 1.05
Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis (1993) 1.01
What is the role of upper airway bacterial cultures in patients with cystic fibrosis? Pediatr Pulmonol (1996) 0.99
Use of bacterial antigen detection in the diagnosis of pediatric lower respiratory tract infections. Pediatrics (1986) 0.98
Influence of body size and gender on control of ventilation. J Appl Physiol (1985) (1986) 0.97
Osteoporosis in patients with cystic fibrosis. Clin Chest Med (1998) 0.95
Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med (2000) 0.95
Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. Contemp Clin Trials (2013) 0.94
Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis. J Am Diet Assoc (1999) 0.92
Bacterial endocarditis due to penicillin-resistant Streptococcus viridans. Clin Pediatr (Phila) (1979) 0.91
Retroviral vectors efficiently transduce basal and secretory airway epithelial cells in vitro resulting in persistent gene expression in organotypic culture. Hum Gene Ther (1996) 0.90
Research on cystic fibrosis: a journey from the Heart House. Am J Respir Crit Care Med (1998) 0.87
Pregnancy in patients with cystic fibrosis. Clin Obstet Gynecol (1996) 0.86
Malignant nerve-sheath tumor with divergent and glandular differentiation in a dog: a case report. Vet Pathol (2002) 0.85
Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations. Chest (1992) 0.85
Life-threatening theophylline toxicity is not predictable by serum levels. Chest (1987) 0.84
Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr (1997) 0.83
Training pulmonary and critical care physicians in outcomes research: should we take the challenge? Am J Respir Crit Care Med (1998) 0.83
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol (2001) 0.82
Radiographic changes in acute exacerbations of cystic fibrosis in adults: a pilot study. AJR Am J Roentgenol (1994) 0.81
Predictors of drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis (1984) 0.79
The complications of diaphyseal fractures in dogs: a review of 100 cases. J Small Anim Pract (1980) 0.79
The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med (2000) 0.78
Customized probability models for severe sepsis: correction and clarification. JAMA (1995) 0.78
Pseudomonal pericarditis complicating cystic fibrosis. Pediatr Pulmonol (1999) 0.77
Palliative respiratory care. Respir Care (2000) 0.77
Humid air increases airway resistance in asthmatic subjects. West J Med (1988) 0.76
Bleomycin-induced pulmonary fibrosis in a patient with rheumatoid arthritis. A possible synergistic effect? West J Med (1989) 0.75
Cyclic nucleotide responses in control and cystic fibrosis labial glands. Am J Physiol (1990) 0.75
Liver function in patients with cystic fibrosis ingesting fish oil. J Pediatr (1994) 0.75
Evaluation of definitions of ARDS. Am J Respir Crit Care Med (1995) 0.75
Update on clinical trials of cystic fibrosis. Curr Opin Pulm Med (1997) 0.75
Potassium release in labial glands from controls and patients with cystic fibrosis. Lab Invest (1989) 0.75
Clinical epidemiology of acute lung injury. Semin Respir Crit Care Med (2001) 0.75
New and emerging therapies for pulmonary complications of cystic fibrosis. Drugs (2001) 0.75
The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med (2001) 0.75
A hypertrophied bronchial circulatory system may participate in gas exchange. Lancet (1998) 0.75
Pulmonary function in subjects at the extremes of stature. Am Rev Respir Dis (1985) 0.75
Unusual presentation of recurrent Wegener's granulomatosis. Chest (1991) 0.75
Cystic fibrosis. Curr Opin Pulm Med (1996) 0.75
Another truly presidential checkup. N Engl J Med (1995) 0.75
Annual tuberculosis screening of hospital employees: an idea lacking supporting data. Am Rev Respir Dis (1988) 0.75
Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin Pharmacol Ther (1993) 0.75
Development of an in vitro model of primate cervical goblet cells. Biorheology (1990) 0.75
Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest (1998) 0.75
Cardiac asystole during an hypoxic drive study in a normal subject. Chest (1984) 0.75
Comparative monovalent cation transport in neonatal and adult red blood cells. Pediatr Res (1984) 0.75
Cystic fibrosis. Curr Opin Pulm Med (1995) 0.75
Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. J Heart Lung Transplant (1997) 0.75